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Urinary Basic Fibroblast
Growth Factor
A Biochemical Marker for Preosseous
Fibroproliferative Lesions in Patients With
Fibrodysplasia Ossificans Progressiva
Frederick Kaplan, MD*,**,f,. Jeffrey Sawyer, MD*; Susan Connorst,.
Karen Keought; l~ileen Shore, PhD*,:t; Francis Gannon, MD*'§;
David Glaser, MD*; j~avid Rocke, PhDI/; Michael Zasloff, MD, PhD*':t;
and Judah Folkman, MDt
Angiogenesis is a prominent histopathologic fea-
ture of preosseous fibroprolifel~ative lesions in
patients who have fibrodysplasi:il ossificans pro-
gressiva. Basic fibroblast growtl11 factor is an ex-
tremely potent in vivo stimulator of angiogenesis,
and has been implicated in the growth of solid tu-
mors. An enzyme linked immull1osorbant assay
icans progressiva (no significant difference), and
8793 pg/g of creatinine in patients with active fi.
brodysplasia ossificans prog~essiva. Female sub-
jects, both normal and with fibrodysplasia ossifi.
cans progressiva, had highelr levels of urinary
basic fibroblast growth factor than did male sub-
jects. There was no correlation of urinary basic
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the organism. 1,2,14,15,19,20,25,27,28,30,34,37,38,40
Basic fibroblast growth factor has been de-
tected in the serum and urine of tumor bear-
ing animals and in the serum and urine of
patients who have a wide spectrum of be-
nign and malignant tumors.28 In the tumori-
genesis pathway from mild fibromatosis to
aggressive fibromatosis, there seems to be a
discrete molecular switch that correlates
with the cellular export of bFGF.21 The pre-
osseous lesions of fibrodysplasia ossificans
progressiva are histologically indistinguish-
able from the fibroproliferative lesions of
aggressive fibromastosis.22 The authors
therefore examined whether bFGF also was
implicated in the preosseous lesions of fi-
brodysplasia ossificans progressiva. In this
article, the authors provide evidence that
urinary bFGF levels are elevated in patients
who have fibrodysplasia ossificans progres-
siva during times of acute flareups of the
disease process.
Embryonic growth and development, frac-
ture healing and wound repair, and tumor
growth and regression are all dependent on
the control of angiogenesis. Angiogenesis is
also an absolute requirement for the forma-
tion and development of the skele-
ton},9,10,12.13,17.32 The angiogenesis that ac-
companies skeletogenesis often is described
as a late event that follows calcification of
cartilage in endochondral ossification.3! Al-
though the absolute requirement for angio-
genesis has been well documented in the late
stages of endochondral osteogenesis, little
attention has been given to the requirement
for angiogenesis during the early stages of
osteogenesis when angiogenic events ac-
company the formation of the mesenchymal
anlage of the skeleton.9,16 This early stage of
skeletal embryogenesis corresponds to the
highly vascularized preosseous fibroprolifer-
ative lesion in patients who have fibrodys-
plasia ossificans progressiva, a rare genetic
disorder of progressive postnatal ectopic os-
, (F ' 1) 22.23,33 teogeneSIs .g.;- '"Z~-"""-""""c J- C'
Basic fibroblastgrow'nl'fa"tt'dt1S'M' ex-
tremely potent heparin binding angiogenic
endothelial cell mitogen involved in the
control of numerous biologic processes that
are critical for development and survival of
MATERL:\LS AND METHODS
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Patients and Controls t;~~~
Sixty-seven patients with fibrodysplasia
cans progressiva were seen in the off site
brodysplasia ossificans progressiva clinic of
University of Pennsylvania Medical Center be-
tween October 1995 and March 1997.
40 females and 27 males ranging in age
J
ossificans progressiva was confirmed in all
tients on the basis of congenital
the great toes, and progressive postnatal
topic ossification in characteristic temporal
anatomic patterns.(25 females; ,
70 years served as control subjects.
Patients were evaluated and categorized
having active flareups of fibrodysplasia -
cans progressiva if they were experiencing
symptoms and signs of acute soft tissue swelling
secondary to the presence of a soft tissue tumor.
Patients were categorized as having inactive dis-
ease if they had not experienced any symptoms
or signs of an acute flareup of fibrodysplasia os-
sificans progressiva during the 3 months before
evaluation.
Fig 1. A medium power photomicrograph of an
early fibroproliferative lesion in a patient with fi-
brodysplasia ossificans progressiva. There are
numerous small vessels (arrows) supported by
a characteristic fibroproliferative stroma. No
bone or cartilage is present. (Stain, hematoxylin
and eosin; original magnification, x250).
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Fig 2. Logarithmic scale of bFGF
levels in normal controls and in
patients with fibrodysplasia ossif-
icans progressiva. Transverse bar
in each column denotes median
bFGF level.
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data suggest, therefore, that urinary bFGF
may be a biochemical marker for preosseous
fibroproliferative tumors in patients who
have fibrodysplasia ossificans progressiva.
Despite these interesting findings, some
precautions are necessary. First, although me-
dian levels of urinarybFPF.weresignificantly
different betweenihose-panehtS with and with-
out active fibroproliferative lesions, there was
a wide range of values within each group and
much overlap between groups (Fig 2). Such
findings may limit the clinical use of individual
bFGF levels in assessing disease activity. Sec-
ond, although the sample size was small and
cross sectional, it represented approximately
1/3 of all patients currently identified with fi-
brodysplasia ossificans progressiva world-
wide. In all, the authors think that the findings
of this study are representative of the disease
activity that may be seen at any time in the fi-
brodysplasia ossificans progressiva commu-
nity. However, further long term longitudinal
studies are necessary to establish the general
applicability of these findings to the molecular
pathophysiology of fibrodysplasia ossificans
progressiva, and to the potential use in moni-
toring disease activity in individual patients.
To date, numerous angiogenic factors have
been identified and include aFGF, bFGF, IL 8,
angiogenin, TGF a, TGF 13, TNF a, prosta-
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gandins, and VEGF. 7.9.10.12.13.17.32 The cells pro-
ducing bFGF during flareups of fibrodysplasia
ossificans progressiva could be plausibly le-
sional fibroblasts or lesional endothelial cells
but the source of the secreted bFGF is un-
known at present. Inflammatory cells such as
ttlonocytes ~s~ are known
ducers of bFGF and may be involved
disease process.6
Basic fibroblast growth factor, BMP, and
TGF ~ are thought to be involved in the early
pathophysiology of fibrodysplasia ossificans
progressiva.6.23.33 These factors plausibly con-
tribute to a cascade of molecular events that
inhibit myogenesis and promote osteogenesis,
leading to the transdifferentiation of muscle to
bone (Fig 3).3.6.8.11.24.26.39.42 Although the exact
relationship between BMP 4 and bFGF sig-
naling remains unknown, recent studies have
shown that BMP 4 and bFGF signal through a
Ras/Rafl AP I pathway, even though their sig-
nals are transduced by totally different fami-
lies of transmembrane receptors.41
Despite the attention that has been focu:;td
on bFGF as an angiogenic factor, it cannot
fully explain the profound edema that accom-
panies the preosseous lesions of fibrodyspla-
sia ossificans progressiva. Vascular endothe-
lial growth factor is also a potent angiogenic
factor that has unique, profound, and immedi-
the
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data presented in the study suggest that a ther-
apeutic approach based on inhibiting the bio-
logic activity of angiogenic peptides may be a
rational approach to consider in treating the
early fibroproliferative lesions of fibrodyspla-
sia ossificans progressiva.
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